Quintet Private Bank Europe S.A. Raises Stock Position in Pfizer Inc. $PFE

Quintet Private Bank Europe S.A. boosted its stake in Pfizer Inc. (NYSE:PFE) by 11.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 521,181 shares of the biopharmaceutical company’s stock after purchasing an additional 52,658 shares during the period. Quintet Private Bank Europe S.A.’s holdings in Pfizer were worth $13,280,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Norges Bank bought a new stake in shares of Pfizer in the second quarter worth $2,270,157,000. Amundi boosted its position in Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Pfizer by 43.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after purchasing an additional 5,662,309 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Pfizer by 84.9% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock worth $183,302,000 after purchasing an additional 3,472,240 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.56 on Wednesday. The stock has a market cap of $145.34 billion, a PE ratio of 14.86 and a beta of 0.46. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The firm has a fifty day moving average price of $25.11 and a 200-day moving average price of $24.81. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PFE shares. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday. Citigroup initiated coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Guggenheim raised their target price on Pfizer from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, November 24th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $28.28.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.